Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)

Atherosclerosis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02394743
• Other study ID #: PET_eGRF
• Status: Completed
• Phase: N/A
• First received: March 16, 2015
• Last updated: September 6, 2016
• Start date: March 2011
• Est. completion date: September 2016

Study information

• Verified date: September 2016
• Source: Korea University
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. Renal insufficiency is close correlation with atherosclerosis and cardiovascular mortality.

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between eGFR and vascular inflammation detected by 18F FDG-PET.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

1. absence of prior cancer diagnosis or remission from cancer at the time of PET imaging and throughout the follow-up period;

2. >=30 years of age;

3. no prior history of cardiovascular disease ; and

4. absence of acute or chronic inflammatory or autoimmune disease (based on documented medical history) or use of chronic anti-inflammatory therapy.

Exclusion Criteria:

1. age <35 years

2. presence of chronic inflammatory disease

3. use of anti-inflammatory medications

4. presence of active malignant cancer (defined as any radiological or pathological evidence of malignant cancer disease or undergoing chemotherapy or radiation therapy within 1 year before initial PET/CT and throughout the inter-scan duration).

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Atherosclerosis

Intervention

Radiation:
• 18FDG-PET

Locations

Country	Name	City	State
Korea, Republic of	Department of Internal Medicine, Korea University College of Medicine	Seoul	VD

Sponsors (1)

Lead Sponsor	Collaborator
Korea University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between vascular inflammatory status measured by 18F FDG-PET and eGFR by Modification of Diet in Renal Disease(MDRD) formula		at 1 day of taking 18F FDG - PET	No